R&D News | pharmaphorum

News

Neurosterix emerges with $63m for neuroscience pipeline

A brand new biotech – Neurosterix – has been formed to take forward neuroscience programmes that originated at Switzerland’s Addex Therapeutics, including a drug for schiz

News

Redx joins C4X in delisting from AIM due to liquidity issues

UK company Redx Pharma has decided it would be better off in private hands than publicly listed on the Alternative Investment Market (AIM), and has started the process of

News

Ipsen licenses Sutro ADC in $900m deal

Ipsen has expanded its oncology pipeline by licensing rights to an antibody-drug conjugate (ADC) for solid tumours from Sutro Biopharma, its first drug in the category.

News

Disappointment for BMS as Zeposia fails Crohn’s study

Bristol-Myers Squibb’s hopes of adding a new indication to the label for S1P modulator Zeposia have been dented after the drug failed a phase 3 trial in Crohn’s disease.

News

Dr Jenna Gregory of the University of Aberdeen

Test could give early warning of motor neuron disease

Scientists have developed a new test for a biomarker in brain tissue that could detect people who will go on to develop motor neuron disease (MND) before they show symptom

News

Can Google Street View data provide heart health insights?

An intriguing new study has suggested that there could be a correlation between the built environment of an area – its buildings, streets, and green spaces – and the risk

Neurosterix emerges with $63m for neuroscience pipeline

Redx joins C4X in delisting from AIM due to liquidity issues

Ipsen licenses Sutro ADC in $900m deal

Disappointment for BMS as Zeposia fails Crohn’s study

Test could give early warning of motor neuron disease

Can Google Street View data provide heart health insights?

UK seeks views on indefinite CE marks for medical devices

How to meet your physicians where they are online

News

Editor's Picks